DCTH

Delcath Systems, which has outperformed other Russell 2000 stocks and healthcare equipment makers by 3x and 8x this year, is due to publish Q3 results on the 9th of Nov. The probability of a topline beat looks high, while a beat over 5% could be taken well; GMs may see a sequential dip but will rebound in Q4. Recent CHOPIN phase II trial success and expansion of active treatment centers enhance DCTH's growth prospects, with 24% topline growth expected in the medium term.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 9, 2026, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Monday, November.

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 34,00.

VLO, PBF, FET and DCTH screen as low-beta picks as volatility rises, backed by refining, energy-equipment and liver-cancer growth drivers.

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.